Next generation sequencing (NGS)

GENETIC8 trials

Conditions

CRCCancerColorectal CancerDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2EndometriosisFamilial HypercholesterolemiaGDM

Unknown Phase

Genetic Causes of Gestational Diabetes in the Emirati Population

NCT03589092

Imperial College London Diabetes CentreGDM, Gestational Diabetes, Maturity-onset Diabetes of the Young +1

Start: 2017-01-01End: 2020-12-31Target: 600Updated: 2020-06-25

Genetic Causes of Hypercholesterolaemia in the Emirati Population

NCT03597958

Imperial College London Diabetes CentreFamilial Hypercholesterolemia

Start: 2017-01-17End: 2020-12-31Target: 1000Updated: 2020-06-25

Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE

NCT03607604

Imperial College London Diabetes CentreDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Maturity-onset Diabetes of the Young

Start: 2015-04-01End: 2021-12-31Target: 778Updated: 2020-08-19

Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics

CompletedNCT03962452

University Hospital TuebingenGenetic Predisposition, Rare Diseases

Start: 2019-03-01End: 2025-02-01Updated: 2025-03-30

Cell-free DNA in Hereditary And High-Risk Malignancies 1

Active, not recruitingNCT04261972

University Health Network, TorontoHereditary Cancer Syndrome

Start: 2018-07-01End: 2026-12-31Updated: 2026-01-14

Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics

CompletedNCT04571801

University Hospital, EssenSepsis, Septic Shock

Start: 2022-03-16End: 2024-04-23Updated: 2025-08-24

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

RecruitingNCT04981119

A2 Biotherapeutics Inc.Cancer, Colorectal Cancer, CRC +14

Start: 2021-10-29End: 2029-04-01Target: 500Updated: 2026-09-03

Endometriosis and Peritoneal Dysbiosis

RecruitingNCT05824819

Jagiellonian UniversityEndometriosis, Infertility Unexplained

Start: 2023-05-01End: 2025-12-30Target: 100Updated: 2025-04-15

Intensive Care Medicine2026-06-30

Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2026-05-28

A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.

Journal of Clinical Oncology2026-05-28

Abstract PS5-08-03: Denali-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with triple-negative breast cancer and other EGFR-expressing solid tumors with HLA-A*02 loss of heterozygosity (LOH)

Clinical Cancer Research2026-02-17

Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.

Journal of Clinical Oncology2025-05-282 citations

EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

Journal of Clinical Oncology2025-05-282 citations

EVEREST-1: Safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

Journal of Clinical Oncology2025-05-282 citations

BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine clinical trials.

Journal of Clinical Oncology2025-05-28

Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

Cancer Research2025-04-25

Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors.

Journal of Clinical Oncology2025-01-27

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2025-01-27

Актуальные клинические исследования таргетной CAR-T терапии солидных опухолей

cyberleninka.ru2025-01-01

Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities

npj Precision Oncology2024-08-0510 citations

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2024-06-015 citations

EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2024-06-014 citations

Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).

Journal of Clinical Oncology2024-05-29

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Regular and Young Investigator Award Abstracts2023-10-313 citations

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Regular and Young Investigator Award Abstracts2023-10-311 citations

Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.

Journal of Clinical Oncology2023-01-24

263 A2B694, an autologous logic-gated cell therapy targeting mesothelin

Regular and Young Investigator Award Abstracts2022-11-013 citations

7 more papers not shown

Next generation sequencing (NGS)

Sponsors

Conditions

Unknown Phase

Related Papers